Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease
Open Access
- 1 November 2015
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Neurology
- Vol. 72 (11), 1275-1280
- https://doi.org/10.1001/jamaneurol.2015.1867
Abstract
The core cerebrospinal fluid (CSF) biomarkers Aβ42, total tau, and tau phosphorylated at threonine 181 (P-tau181) reflect the neuropathological hallmarks of Alzheimer disease (AD), amyloid plaques, and neurofibrillary tangles.1 Clinically, AD is characterized by cognitive decline, but once a patient has AD pathology, these core CSF biomarkers appear not to reflect further functional decline owing to their relative stability during clinical AD.2-4Keywords
This publication has 30 references indexed in Scilit:
- Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's diseaseAlzheimer's & Dementia, 2014
- Early Aβ accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brainNeurology, 2004
- CSF markers for incipient Alzheimer's diseaseThe Lancet Neurology, 2003
- Small Proteins that Modulate Calmodulin-Dependent Signal TransductionMolecular Neurobiology, 2000
- Neurochemical Dissection of Synaptic Pathology in Alzheimer's DiseaseInternational Psychogeriatrics, 1998
- Dendritic Translocation of RC3/Neurogranin mRNA in Normal Aging, Alzheimer Disease and Fronto-Temporal DementiaJournal of Neuropathology and Experimental Neurology, 1997
- Synaptic pathology in Alzheimer's disease: Relation to severity of dementia, but not to senile plaques, neurofibrillary tangles, or the ApoE4 alleleJournal of Neural Transmission, 1996
- Vascular dementiaNeurology, 1993
- Neuropathological stageing of Alzheimer-related changesActa Neuropathologica, 1991
- Clinical diagnosis of Alzheimer's diseaseNeurology, 1984